Skip to main content
. 2022 Mar 3;6(5):1490–1498. doi: 10.1182/bloodadvances.2021005357

Table 2.

Patient characteristics at enrollment

Characteristic Total (%)
(n = 35)
A
IBR 280
VEN 200
(n = 2)
B
IBR 420
VEN 200
(n = 16)
C
IBR 280
VEN 400
(n = 8)
D
IBR 560
VEN 200
(n = 4)
E
IBR 420
VEN 400
(n = 5)
Mean age in years (min-max) 63 (49-82) 75 (69-82) 62 (54-76) 66 (49-79) 62 (53-68) 56 (50-60)
% male 29 (83%) 2 (100%) 14 (87%) 6 (75%) 3 (75%) 4 (80%)
Prior auto transplant (yes), % 15 (43%) 0 (0%) 8 (50%) 4 (50%) 1 (25%) 2 (40%)
Refractory to last line of therapy (yes), % 18 (51%) 2 (100%) 5 (31%) 4 (50%) 3 (75%) 4 (80%)
Lines of prior Rx
 1 line 20 (57%) 1 (50%) 12 (75%) 3 (38%) 3 (75%) 1 (20%)
 2 lines 13 (37%) 1 (50%) 4 (25%) 3 (38%) 1 (25%) 4 (80%)
 3 lines 2 (6%) 0 (0%) 0 (0%) 2 (25%) 0 (0%) 0 (0%)
Stage at enrollment
 1-2 2 (6%) 0 (0%) 1 (6%) 0 (0%) 1 (25%) 0 (0%)
 3 6 (17%) 1 (50%) 2 (13%) 1 (13%) 1 (25%) 1 (20%)
 4 27 (77%) 1 (50%) 13 (81%) 7 (88%) 2 (50%) 4 (80%)
MIPI at enrollment
 Low 17 (49%) 1 (50%) 9 (56%) 2 (25%) 2 (50%) 3 (60%)
 Intermediate 12 (34%) 1 (50%) 5 (31%) 2 (25%) 2 (50%) 2 (40%)
 High 6 (17%) 0 (0%) 2 (13%) 4 (50%) 0 (0%) 0 (0%)